Open Access

Central tolerance requires a Bim

  • Erik Peterson1
Arthritis Research & Therapy20024:76100

https://doi.org/10.1186/ar-2002-76100

Received: 12 March 2002

Accepted: 27 March 2002

Published: 27 March 2002

Keywords

Bim knockout mice negative selection

Context

"Negative selection" or deletion of potentially autoreactive immature thymocytes occurs by apoptosis of cells bearing an antigen receptor with high affinity for self major histocompatibility complex (MHC). The molecular requirements for thymocyte apoptosis induced during negative selection are beginning to be defined. Functional defects in the signaling cascade downstream of the T-cell antigen receptor (e.g. mutations in CD3?, the adaptors Grb2 and Gads, the kinases Itk and Rlk) have already been associated with impaired deletion. In contrast, and perhaps surprisingly, proteins known to play a role in apoptosis induced by "death receptor" ligation (e.g. CD95, FADD, Caspase-8) have limited roles in thymocyte deletion. The present paper is, therefore, among the first to show that mutation of a protein within the machinery of death influences thymocyte apoptosis.

Significant findings

Bim is a proapoptotic member, containing only the BH3 domain, of the Bcl-2 family of intracellular membrane proteins. Aging Bim knockout mice exhibit autoantibody production and immune complex glomerulonephritis (see Additional information [1]). Here, evidence is presented that autoimmunity in Bim-deficient animals is associated with defective negative thymic selection. The authors employ in vivo and in vitro anti-T-cell receptor (TCR) treatment, exposure to endogenous and exogenous superantigen, and several TCR-transgenic models to examine thymocyte deletion. Results are consistent throughout; Bim deficient thymocytes are refractory to apoptosis induced by TCR engagement. The authors show evidence that TCR engagement normally results in enhanced Bim protein levels and increased association between Bim and Bcl-XL. The Bim-Bcl-XL complex may impair antiapoptotic function of Bcl-XL. The authors conclude that Bim is required for TCR-mediated apoptosis and deletion of autoreactive thymocytes.

Comments

Recent work in other autoimmune animal models has suggested that perturbations in thymocyte selection may alter the threshold for autoimmune phenomena. Bim-deficient animals show parallels with nonobese diabetic (NOD) mice (see Additional information [2]) and "motheaten" mice (lacking the signaling protein SHP-1) (see Additional information [3]); each exhibits defects in thymic selection. A causal link between autoimmune phenomena and skewed thymic development in these mice remains to be demonstrated, such that it is unclear if defects in peripheral tolerance contribute to autoimmunity. One experimental approach would be to "rescue" thymic selection in Bim-deficient mice through reconstitution with a thymocyte-restricted transgenic form of Bim. In such a system, Bim protein would be engineered to be present during T-cell development, yet absent in mature peripheral T cells. Those autoimmune features dependent upon thymic development should, therefore, be eliminated.

Methods

Knockout mice

Additional information

1. Bouillet P, Metcalf D, Huang DC, Tarlinton DM, Kay TW, Kontgen F, Adams JM, Strasser A: Proapoptotic Bcl-2 relative Bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunity. Science 1999, 286:1735-1738.

2. Kishimoto H, Sprent J: A defect in central tolerance in NOD mice. Nat Immunol 2001, 2:1025-1031.

3. Zhang J, Somani AK, Yuen D, Yang Y, Love PE, Siminovitch KA: Involvement of the SHP-1 tyrosine phosphatase in regulation of T cell selection. J Immunol 1999, 163:3012-3021.

Authors’ Affiliations

(1)
University of Pennsylvania

References

  1. Bouillet P, Purton JF, Godfrey DI, Zhang LC, Coultas L, Puthalakath H, Pellegrini M, Cory S, Adams JM, Strasser A: BH3-only Bcl-2 family member Bim is required for apoptosis of autoreactive thymocytes. Nature. 2002, 415: 922-926.PubMedView ArticleGoogle Scholar

Copyright

© Biomed Central Ltd 2002

Advertisement